Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

(2022) D Husereau et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

THE DIRECT COSTS BURDEN OF BEVACIZUMAB IN SOUTH-WEST ROMANIA

(2022) VALENTINA GHIMPĂU   FARMACIA

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection

(2022) Yi-Chia Su et al.   Cancers

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer

(2021) Shing Fung Lee et al.   Frontiers in Oncology

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

(2021) Yujiro Nishizawa et al.   BMC CANCER

Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review

(2021) Stavroula Koilakou et al.   Molecular Diagnosis & Therapy

Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia

(2021) Shereef Elsamany et al.   Value in Health Regional Issues

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

(2020) Jiaqi Han et al.   Cancer Control

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study

(2020) Sebastian Stintzing et al.   JOURNAL OF MEDICAL ECONOMICS

Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China

(2020) Lin Shen et al.   JOURNAL OF MEDICAL ECONOMICS

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

(2020) IRENA SEHNALOVA   FARMACIA

Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival

(2020) Syed H. Zaidi et al.   Nature Communications

Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer

(2019) S. Bazarbashi et al.   Current Oncology

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

(2019) Bobo Zheng et al.   BMC CANCER

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer

(2019) Liangliang Bai et al.   Cancer Management and Research

New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer

(2018) Julia Sánchez-Gundín et al.   International Journal of Medical Sciences

Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis

(2018) Toshihiro Shida et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer

(2018) Dawon Park et al.   Annals of Surgical Treatment and Research

First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs

(2018) Jacopo Giuliani et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

(2018) Wânia Cristina da Silva et al.   BIODRUGS

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

(2018) Jaafar Bennouna et al.   JAMA Oncology

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients

(2017) Surajit Pathak et al.   Oncotarget

The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials

(2016) Jacopo Giuliani et al.   Clinical Colorectal Cancer

Population-Based Preference Weights for the EQ-5D Health States Using the Visual Analogue Scale (VAS) in Iran

(2016) Reza Goudarzi et al.   Iranian Red Crescent Medical Journal

Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada

(2015) M. Pettigrew et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer

(2014) E.M. Ewara et al.   Current Oncology

Sequencing of treatment in metastatic colorectal cancer: Where to fit the target

(2014) Sally Temraz   WORLD JOURNAL OF GASTROENTEROLOGY

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

(2013) A. Lange et al.   EUROPEAN JOURNAL OF CANCER

Economic evaluation of monoclonal antibody in the management of colorectal cancer in Malaysia

(2012) MS Natrah et al.   BMC HEALTH SERVICES RESEARCH

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

(2011) C. Suzuki et al.   ANNALS OF ONCOLOGY

Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting

(2011) Christian Asseburg et al.   CLINICAL THERAPEUTICS

The dimensions of the CRC problem

(2010) L.v. Karsa et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Equivalence of two healthcare costing methods: bottom-up and top-down

(2008) Michael K. Chapko et al.   HEALTH ECONOMICS

Administration of Cetuximab Every 2 Weeks in the Treatment of Metastatic Colorectal Cancer: An Effective, More Convenient Alternative to Weekly Administration?

(2008) J. Tabernero et al.   ONCOLOGIST